Today news
About the same in other media
Biocon unit gets USFDA nod for generic drug
Reading now: 934
Biocon said its subsidiary has received approval from the US health regulator to market a generic medication to treat chronic heart failure. Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing.
Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.
The medicine is also used to treat paediatric patients over the age of one year.
The approval further adds to Biocon's portfolio of vertically integrated, complex drug products, the company said.
(You can now subscribe to our Economic Times WhatsApp channel)
Read more on economictimes.indiatimes.com
About this in other media
Bitcoin In September ‘Seasonal Slog’: What Opportunities Should Traders Watch For? cryptonews.com /3 months ago
New York site chosen for factory to build high-speed trains for Las Vegas-California line abcnews.go.com /3 months ago
Big Lots files for bankruptcy, will close some stores amid sale to investment firm foxbusiness.com /3 months ago
Show more
The website fvbb.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
